Reuters logo
BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Bruno Farmaceutici S.p.A. for Mysimba in Italy
March 27, 2017 / 10:56 PM / in 8 months

BRIEF-Orexigen Therapeutics announces commercialization and distributorship agreement with Bruno Farmaceutici S.p.A. for Mysimba in Italy

March 27 (Reuters) - Orexigen Therapeutics Inc

* Orexigen Therapeutics announces commercialization and distributorship agreement with Bruno Farmaceutici S.p.A. for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) in Italy

* Orexigen Therapeutics Inc- Under terms of agreement, Bruno will be responsible for all commercialization activity and expenses

* Orexigen Therapeutics Inc says Bruno expects that Mysimba will be available for patients in Italy in Q4 of this year

* Orexigen Therapeutics Inc - Orexigen Therapeutics Ireland, Bruno Farmaceutici executed a distributorship agreement for Mysimba in Italy

* Orexigen Therapeutics-Under deal co to supply Mysimba to Bruno for negotiated transfer price, upfront milestone payments at signing, first commercial sale Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below